Puma Biotechnology (PBYI) 234.00 $PBYI Pharma S
Post# of 273330
Posted On: 03/22/2015 4:04:53 AM
Puma Biotechnology (PBYI) 234.00 $PBYI
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
BIIB: 475.98 (+42.33), ACT: 317.06 (+2.65), VRX: 204.26 (+2.17), PCYC: 257.85 (-0.21), OSIR: 17.59 (-0.89), ACOR: 34.74 (-0.39), HSP: 87.64 (-0.06), AGN: 240.22 (+2.88), MDVN: 135.56 (+1.09), ESRX: 85.38 (+1.43), SHPG: 253.64 (+3.07), ABBV: 60.40 (-0.79), SNY: 50.64 (+1.17), ARNA: 4.80 (-0.21), REGN: 488.87 (+2.85), ABT: 47.47 (+0.03), ENDP: 92.37 (+0.89), AKRX: 49.03 (-0.41), PFE: 34.25 (+0.10), INCY: 95.55 (-1.53), SLXP: 172.80 (+0.26), AMGN: 170.10 (+0.99), MYL: 63.06 (-0.88), LLY: 76.12 (+1.90), BMY: 67.76 (-0.56), GSK: 48.81 (+0.60), ALKS: 67.20 (-0.86), MNKD: 5.26 (-0.28), OREX: 7.19 (-0.41), NVO: 49.53 (+1.33), ISIS: 73.59 (-3.49), GERN: 3.98 (-0.15), AZN: 72.70 (+1.80), MRK: 58.58 (+0.37), PBYI: 234.00 (-15.71), NVS: 101.68 (+1.81)
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
BIIB: 475.98 (+42.33), ACT: 317.06 (+2.65), VRX: 204.26 (+2.17), PCYC: 257.85 (-0.21), OSIR: 17.59 (-0.89), ACOR: 34.74 (-0.39), HSP: 87.64 (-0.06), AGN: 240.22 (+2.88), MDVN: 135.56 (+1.09), ESRX: 85.38 (+1.43), SHPG: 253.64 (+3.07), ABBV: 60.40 (-0.79), SNY: 50.64 (+1.17), ARNA: 4.80 (-0.21), REGN: 488.87 (+2.85), ABT: 47.47 (+0.03), ENDP: 92.37 (+0.89), AKRX: 49.03 (-0.41), PFE: 34.25 (+0.10), INCY: 95.55 (-1.53), SLXP: 172.80 (+0.26), AMGN: 170.10 (+0.99), MYL: 63.06 (-0.88), LLY: 76.12 (+1.90), BMY: 67.76 (-0.56), GSK: 48.81 (+0.60), ALKS: 67.20 (-0.86), MNKD: 5.26 (-0.28), OREX: 7.19 (-0.41), NVO: 49.53 (+1.33), ISIS: 73.59 (-3.49), GERN: 3.98 (-0.15), AZN: 72.70 (+1.80), MRK: 58.58 (+0.37), PBYI: 234.00 (-15.71), NVS: 101.68 (+1.81)
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 47.47 (+0.03), NWBO: 7.63 (-0.19), ZIOP: 13.89 (-0.11), PCYC: 257.85 (-0.21), CVM: 1.11 (unch), PFE: 34.25 (+0.10), CLDX: 30.38 (-1.40), IMGN: 7.44 (-0.48), BMY: 67.76 (-0.56), RIGL: 3.45 (-0.06), INO: 9.09 (-0.36), KITE: 71.89 (-1.62), LH: 126.80 (+0.54), ABBV: 60.40 (-0.79), PBYI: 234.00 (-15.71)
Puma Biotechnology Up on Neratinib Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 4:41PM CDT
Puma Biotechnology (PBYI) announced the initiation of a phase II study on neratinib.
CYTK: 7.76 (-0.19), PFE: 34.25 (+0.10), PBYI: 234.00 (-15.71)
Puma Bio initiates Phase 2 study of neratinib in breast cancer
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 11:57AM CDT
PBYI: 234.00 (-15.71)
Should Gilead Acquire Puma Biotechnology?
Tim Harrison - at Seeking Alpha - Tue Mar 10, 11:44AM CDT
GILD: 102.29 (+0.85), PBYI: 234.00 (-15.71)
Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer
Business Wire - Tue Mar 10, 8:05AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the initiation of a Phase II trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant treatment of breast cancer.
PBYI: 234.00 (-15.71)
Biotech Stock Mailbag: Next Biotech Takeout Targets, NewLink Genetics
at The Street - Fri Mar 06, 4:30AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
MDVN: 135.56 (+1.09), NLNK: 54.57 (-1.36), PBYI: 234.00 (-15.71)
The Under-the-Radar Reason Why Puma Biotechnology Inc. Rocketed 17% Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 05, 2:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Puma Biotechnology , a clinical-stage...
PCYC: 257.85 (-0.21), ABBV: 60.40 (-0.79), PBYI: 234.00 (-15.71)
Puma Biotechnology beats by $0.16
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:43PM CST
PBYI: 234.00 (-15.71)
Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results
Business Wire - Mon Mar 02, 3:15PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2014.
PBYI: 234.00 (-15.71)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 34.10 (-0.41), CASM: 1.38 (+0.10), AMRN: 2.52 (-0.03), XON: 46.11 (-1.26), OSIR: 17.59 (-0.89), CPIX: 6.78 (-0.15), AMED: 26.74 (-0.25), CTIC: 1.93 (unch), INSY: 60.02 (-0.82), ECYT: 5.96 (-0.06), CMRX: 40.61 (-1.50), KYTH: 48.22 (+0.21), TRIB: 19.39 (+0.45), GALE: 1.46 (-0.03), ARNA: 4.80 (-0.21), XLRN: 41.82 (-0.62), ACRX: 4.15 (-0.09), ENDP: 92.37 (+0.89), DPLO: 27.89 (+0.81), SLXP: 172.80 (+0.26), PPHM: 1.49 (-0.04), MYL: 63.06 (-0.88), CBPO: 87.55 (-0.10), RGEN: 32.32 (-1.09), HALO: 14.63 (-1.43), ALIM: 5.12 (+0.08), ACHN: 11.06 (-0.36), GERN: 3.98 (-0.15), DARA: 0.82 (unch), SCMP: 17.89 (-0.67), ICPT: 290.98 (+2.47), CDXS: 3.80 (unch), PCRX: 97.64 (-0.08), PBYI: 234.00 (-15.71), FOLD: 11.61 (-0.85)
Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets' Global Healthcare Conference
Business Wire - Wed Feb 18, 3:07PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will participate in an analyst-led fireside chat at 11:30 a.m. EST on Wednesday, February 25, at the 2015 RBC Capital Markets Global Healthcare Conference. The conference will be held at the New York Palace Hotel in New York City.
PBYI: 234.00 (-15.71)
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 135.56 (+1.09), BLUE: 124.76 (-1.64), BIIB: 475.98 (+42.33), GILD: 102.29 (+0.85), ALXN: 187.71 (-1.36), TGTX: 18.22 (-0.60), TKMR: 19.48 (-1.01), ANAC: 54.24 (-1.88), PBYI: 234.00 (-15.71), REGN: 488.87 (+2.85)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology, Inc.
PR Newswire - Tue Feb 10, 7:45AM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Puma Biotechnology, Inc. ("Puma Biotechnology" or the "Company"
(NYSE: PBYI -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
PBYI: 234.00 (-15.71)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Puma Biotechnology, Inc. (PBYI) To Contact The Firm
PR Newswire - Mon Feb 09, 3:00PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Puma Biotechnology, Inc. ("Puma" or the "Company" (NYSE: PBYI).
PBYI: 234.00 (-15.71)
3 All-or-Nothing Biotech Stocks We're Closely Watching
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:10AM CST
There may be no other industry as prone to hit-or-miss investments as biotechnology. An astounding 90% of drugs that enter phase 1 clinical trials never reach commercialization, and that means failure is far more common than success. As a result,...
JNJ: 102.40 (+0.71), ESPR: 112.33 (+2.19), GERN: 3.98 (-0.15), PFE: 34.25 (+0.10), MRK: 58.58 (+0.37), INCY: 95.55 (-1.53), AMGN: 170.10 (+0.99), SNY: 50.64 (+1.17), REGN: 488.87 (+2.85), PBYI: 234.00 (-15.71)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Puma Biotechnology, Inc. - PBYI
PR Newswire - Fri Feb 06, 1:31PM CST
Pomerantz LLP is investigating claims on behalf of investors of Puma Biotechnology, Inc. ("Puma" or the "Company" (NYSE: PBYI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
PBYI: 234.00 (-15.71)
Puma Biotechnology to Present at Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 3:05PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 8:30 a.m. EST on Thursday, February 12, at the 2015 Leerink Global Healthcare Conference. The conference will be held at the Waldorf Astoria Hotel in New York City.
PBYI: 234.00 (-15.71)
Puma Biotechnology Closes $218 Million Public Offering of Common Stock
Business Wire - Tue Jan 27, 1:36PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the closing of an underwritten registered public offering of 1,150,000 shares of its common stock at a price to the public of $190.00 per share. The shares of common stock issued in the offering included 150,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. The net proceeds from the offering were approximately $205 million, after deducting the underwriting discount and estimated offering expenses payable by the Company.
JPM: 61.75 (+0.55), PBYI: 234.00 (-15.71)
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
BIIB: 475.98 (+42.33), ACT: 317.06 (+2.65), VRX: 204.26 (+2.17), PCYC: 257.85 (-0.21), OSIR: 17.59 (-0.89), ACOR: 34.74 (-0.39), HSP: 87.64 (-0.06), AGN: 240.22 (+2.88), MDVN: 135.56 (+1.09), ESRX: 85.38 (+1.43), SHPG: 253.64 (+3.07), ABBV: 60.40 (-0.79), SNY: 50.64 (+1.17), ARNA: 4.80 (-0.21), REGN: 488.87 (+2.85), ABT: 47.47 (+0.03), ENDP: 92.37 (+0.89), AKRX: 49.03 (-0.41), PFE: 34.25 (+0.10), INCY: 95.55 (-1.53), SLXP: 172.80 (+0.26), AMGN: 170.10 (+0.99), MYL: 63.06 (-0.88), LLY: 76.12 (+1.90), BMY: 67.76 (-0.56), GSK: 48.81 (+0.60), ALKS: 67.20 (-0.86), MNKD: 5.26 (-0.28), OREX: 7.19 (-0.41), NVO: 49.53 (+1.33), ISIS: 73.59 (-3.49), GERN: 3.98 (-0.15), AZN: 72.70 (+1.80), MRK: 58.58 (+0.37), PBYI: 234.00 (-15.71), NVS: 101.68 (+1.81)
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
BIIB: 475.98 (+42.33), ACT: 317.06 (+2.65), VRX: 204.26 (+2.17), PCYC: 257.85 (-0.21), OSIR: 17.59 (-0.89), ACOR: 34.74 (-0.39), HSP: 87.64 (-0.06), AGN: 240.22 (+2.88), MDVN: 135.56 (+1.09), ESRX: 85.38 (+1.43), SHPG: 253.64 (+3.07), ABBV: 60.40 (-0.79), SNY: 50.64 (+1.17), ARNA: 4.80 (-0.21), REGN: 488.87 (+2.85), ABT: 47.47 (+0.03), ENDP: 92.37 (+0.89), AKRX: 49.03 (-0.41), PFE: 34.25 (+0.10), INCY: 95.55 (-1.53), SLXP: 172.80 (+0.26), AMGN: 170.10 (+0.99), MYL: 63.06 (-0.88), LLY: 76.12 (+1.90), BMY: 67.76 (-0.56), GSK: 48.81 (+0.60), ALKS: 67.20 (-0.86), MNKD: 5.26 (-0.28), OREX: 7.19 (-0.41), NVO: 49.53 (+1.33), ISIS: 73.59 (-3.49), GERN: 3.98 (-0.15), AZN: 72.70 (+1.80), MRK: 58.58 (+0.37), PBYI: 234.00 (-15.71), NVS: 101.68 (+1.81)
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 47.47 (+0.03), NWBO: 7.63 (-0.19), ZIOP: 13.89 (-0.11), PCYC: 257.85 (-0.21), CVM: 1.11 (unch), PFE: 34.25 (+0.10), CLDX: 30.38 (-1.40), IMGN: 7.44 (-0.48), BMY: 67.76 (-0.56), RIGL: 3.45 (-0.06), INO: 9.09 (-0.36), KITE: 71.89 (-1.62), LH: 126.80 (+0.54), ABBV: 60.40 (-0.79), PBYI: 234.00 (-15.71)
Puma Biotechnology Up on Neratinib Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 4:41PM CDT
Puma Biotechnology (PBYI) announced the initiation of a phase II study on neratinib.
CYTK: 7.76 (-0.19), PFE: 34.25 (+0.10), PBYI: 234.00 (-15.71)
Puma Bio initiates Phase 2 study of neratinib in breast cancer
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 11:57AM CDT
PBYI: 234.00 (-15.71)
Should Gilead Acquire Puma Biotechnology?
Tim Harrison - at Seeking Alpha - Tue Mar 10, 11:44AM CDT
GILD: 102.29 (+0.85), PBYI: 234.00 (-15.71)
Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer
Business Wire - Tue Mar 10, 8:05AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the initiation of a Phase II trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant treatment of breast cancer.
PBYI: 234.00 (-15.71)
Biotech Stock Mailbag: Next Biotech Takeout Targets, NewLink Genetics
at The Street - Fri Mar 06, 4:30AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
MDVN: 135.56 (+1.09), NLNK: 54.57 (-1.36), PBYI: 234.00 (-15.71)
The Under-the-Radar Reason Why Puma Biotechnology Inc. Rocketed 17% Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 05, 2:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Puma Biotechnology , a clinical-stage...
PCYC: 257.85 (-0.21), ABBV: 60.40 (-0.79), PBYI: 234.00 (-15.71)
Puma Biotechnology beats by $0.16
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:43PM CST
PBYI: 234.00 (-15.71)
Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results
Business Wire - Mon Mar 02, 3:15PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2014.
PBYI: 234.00 (-15.71)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 34.10 (-0.41), CASM: 1.38 (+0.10), AMRN: 2.52 (-0.03), XON: 46.11 (-1.26), OSIR: 17.59 (-0.89), CPIX: 6.78 (-0.15), AMED: 26.74 (-0.25), CTIC: 1.93 (unch), INSY: 60.02 (-0.82), ECYT: 5.96 (-0.06), CMRX: 40.61 (-1.50), KYTH: 48.22 (+0.21), TRIB: 19.39 (+0.45), GALE: 1.46 (-0.03), ARNA: 4.80 (-0.21), XLRN: 41.82 (-0.62), ACRX: 4.15 (-0.09), ENDP: 92.37 (+0.89), DPLO: 27.89 (+0.81), SLXP: 172.80 (+0.26), PPHM: 1.49 (-0.04), MYL: 63.06 (-0.88), CBPO: 87.55 (-0.10), RGEN: 32.32 (-1.09), HALO: 14.63 (-1.43), ALIM: 5.12 (+0.08), ACHN: 11.06 (-0.36), GERN: 3.98 (-0.15), DARA: 0.82 (unch), SCMP: 17.89 (-0.67), ICPT: 290.98 (+2.47), CDXS: 3.80 (unch), PCRX: 97.64 (-0.08), PBYI: 234.00 (-15.71), FOLD: 11.61 (-0.85)
Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets' Global Healthcare Conference
Business Wire - Wed Feb 18, 3:07PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will participate in an analyst-led fireside chat at 11:30 a.m. EST on Wednesday, February 25, at the 2015 RBC Capital Markets Global Healthcare Conference. The conference will be held at the New York Palace Hotel in New York City.
PBYI: 234.00 (-15.71)
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 135.56 (+1.09), BLUE: 124.76 (-1.64), BIIB: 475.98 (+42.33), GILD: 102.29 (+0.85), ALXN: 187.71 (-1.36), TGTX: 18.22 (-0.60), TKMR: 19.48 (-1.01), ANAC: 54.24 (-1.88), PBYI: 234.00 (-15.71), REGN: 488.87 (+2.85)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology, Inc.
PR Newswire - Tue Feb 10, 7:45AM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Puma Biotechnology, Inc. ("Puma Biotechnology" or the "Company"
(NYSE: PBYI -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. PBYI: 234.00 (-15.71)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Puma Biotechnology, Inc. (PBYI) To Contact The Firm
PR Newswire - Mon Feb 09, 3:00PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Puma Biotechnology, Inc. ("Puma" or the "Company"
(NYSE: PBYI). PBYI: 234.00 (-15.71)
3 All-or-Nothing Biotech Stocks We're Closely Watching
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:10AM CST
There may be no other industry as prone to hit-or-miss investments as biotechnology. An astounding 90% of drugs that enter phase 1 clinical trials never reach commercialization, and that means failure is far more common than success. As a result,...
JNJ: 102.40 (+0.71), ESPR: 112.33 (+2.19), GERN: 3.98 (-0.15), PFE: 34.25 (+0.10), MRK: 58.58 (+0.37), INCY: 95.55 (-1.53), AMGN: 170.10 (+0.99), SNY: 50.64 (+1.17), REGN: 488.87 (+2.85), PBYI: 234.00 (-15.71)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Puma Biotechnology, Inc. - PBYI
PR Newswire - Fri Feb 06, 1:31PM CST
Pomerantz LLP is investigating claims on behalf of investors of Puma Biotechnology, Inc. ("Puma" or the "Company"
(NYSE: PBYI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. PBYI: 234.00 (-15.71)
Puma Biotechnology to Present at Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 3:05PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 8:30 a.m. EST on Thursday, February 12, at the 2015 Leerink Global Healthcare Conference. The conference will be held at the Waldorf Astoria Hotel in New York City.
PBYI: 234.00 (-15.71)
Puma Biotechnology Closes $218 Million Public Offering of Common Stock
Business Wire - Tue Jan 27, 1:36PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the closing of an underwritten registered public offering of 1,150,000 shares of its common stock at a price to the public of $190.00 per share. The shares of common stock issued in the offering included 150,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. The net proceeds from the offering were approximately $205 million, after deducting the underwriting discount and estimated offering expenses payable by the Company.
JPM: 61.75 (+0.55), PBYI: 234.00 (-15.71)
(0)
(0)